Interstitial Lung Disease in Systemic Sclerosis

  • Athol U. Wells
  • George A. Margaritopoulos
  • Katerina M. Antoniou
  • Andrew G. Nicholson
Chapter

Abstract

The last decade has seen major advances in the prognostic evaluation and treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD). Risk factors for the development of SSc-ILD include diffuse cutaneous disease and the presence of autoantibodies against topoisomerase I. Accumulated evidence indicative of a genetic predisposition to SSc has yet to provide added clinical value. High resolution computed tomography is highly sensitive in the identification of SSc-ILD but the identification of clinically significant requires the multidisciplinary integration of pulmonary function tests, CT data and the degree of exercise intolerance. Reversible inflammatory disease predominates in a minority of patients but in most cases, prevention of progression of pulmonary fibrosis is the most realistic therapeutic goal. Routine treatment largely consists of immunosuppressive therapy, with proof of concept provided by treatment effects in two controlled trials of cyclophosphamide. Based on these data, the current consensus is that cyclophosphamide therapy is appropriate when SSc-ILD is extensive or overtly progressive. However, historical immunosuppressive agents are only partially efficacious. Rituximab may have an important future role, based on promising pilot data, and there is now an opportunity to evaluate anti-fibrotic agents with treatment effects in other fibrotic interstitial lung diseases. However, when SSc-ILD is limited and non-progressive, an initial policy of non-intervention and careful observation is often warranted.

Keywords

Placebo Permeability Surfactant Corticosteroid Cysteine 

References

  1. 1.
    Chifflot H, Fautzi B, Sordet C, et al. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum. 2008;37:223–35.PubMedCrossRefGoogle Scholar
  2. 2.
    American Thoracic Society/European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med. 2002;165:277–304.CrossRefGoogle Scholar
  3. 3.
    Tyndal AJ, Banert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010;69:1809–15.CrossRefGoogle Scholar
  4. 4.
    Steen VD, Conte C, Owens GR, Medsger Jr TA. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum. 1994;37:1283–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Mayes MD, Lacey Jr JV, Beebe-Dimmer J, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003;48:2246–55.PubMedCrossRefGoogle Scholar
  6. 6.
    Reveille JD. Ethnicity and race and systemic sclerosis: how it affects susceptibility, severity, antibody genetics, and clinical manifestations. Curr Rheumatol Rep. 2003;5:160–7.PubMedCrossRefGoogle Scholar
  7. 7.
    D’Angelo WA, Fries JF, Masi AT, Shulman LE. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med. 1969;46:428–40.PubMedCrossRefGoogle Scholar
  8. 8.
    Travis WD, Costabel U, Hansell DM, ATS/ERS Committee on Idiopathic Interstitial Pneumonias, et al. An official American Thoracic Society/European Respiratory Society statement: update on the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188:733–48.PubMedCrossRefGoogle Scholar
  9. 9.
    Tansey D, Wells AU, Colby TV, et al. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology. 2004;44:585–96.PubMedCrossRefGoogle Scholar
  10. 10.
    Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998;157:199–203.PubMedCrossRefGoogle Scholar
  11. 11.
    Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med. 2002;165:1581–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Fischer A, Swigris JJ, Groshong SD, et al. Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival. Chest. 2008;134:601–5.PubMedCrossRefGoogle Scholar
  13. 13.
    Launay D, Remy-Jardin M, Michon-Pasturel U, et al. High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. J Rheumatol. 2006;33:1789–801.PubMedGoogle Scholar
  14. 14.
    De Santis M, Bosello S, La Torre G, et al. Functional, radiological and biological markers of alveolitis and infections of the lower respiratory tract in patients with systemic sclerosis. Respir Res. 2005;17(6):96.CrossRefGoogle Scholar
  15. 15.
    Desai SR, Veeraraghavan S, Hansell DM, et al. CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology. 2004;232:560–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Wells AU, Cullinan P, Hansell DM, et al. Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med. 1994;149:1583–90.PubMedCrossRefGoogle Scholar
  17. 17.
    Daniil ZD, Gilchrist FC, Nicholson AG, et al. A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med. 1999;160:899–905.PubMedCrossRefGoogle Scholar
  18. 18.
    Kocheril SV, Appleton BE, Somers EC, et al. Comparison of disease progression and mortality of connective tissue disease-related interstitial lung disease and idiopathic interstitial pneumonia. Arthritis Rheum. 2005;53:549–57.PubMedCrossRefGoogle Scholar
  19. 19.
    Tashkin DP, Elashoff R, Clements PJ, Scleroderma Lung Study Research Group, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354:2655–66.PubMedCrossRefGoogle Scholar
  20. 20.
    Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008;177:1248–54.PubMedCrossRefGoogle Scholar
  21. 21.
    Walker UA, Tyndall A, Czirják L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis. 2007;66:754–63.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Briggs DC, Vaughan RW, Welsh KI, et al. Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis. Lancet. 1991;338:661–2.PubMedCrossRefGoogle Scholar
  23. 23.
    Gilchrist FC, Bunn C, Foley PJ, et al. Class II HLA associations with autoantibodies in scleroderma: a highly significant role for HLA-DP. Genes Immun. 2001;2:76–81.PubMedCrossRefGoogle Scholar
  24. 24.
    Kuwana M, Kaburaki J, Mimori T, Kawakami Y, Tojo T. Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis. Arthritis Rheum. 2000;43:1074–84.PubMedCrossRefGoogle Scholar
  25. 25.
    Hu PQ, Fertig N, Medsger Jr TA, Wright TM. Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthritis Rheum. 2003;48:1363–73.PubMedCrossRefGoogle Scholar
  26. 26.
    Reveille JD, Solomon DH, American College of Rheumatology Ad Hoc Committee of Immunologic Testing Guidelines. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum. 2003;49:399–412.PubMedCrossRefGoogle Scholar
  27. 27.
    Feghali-Bostwick C, Medsger Jr TA, Wright TM. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum. 2003;48:1956–63.PubMedCrossRefGoogle Scholar
  28. 28.
    Zhou X, Tan FK, Wang N, et al. Genome-wide association study for regions of systemic sclerosis susceptibility in a Choctaw Indian population with high disease prevalence. Arthritis Rheum. 2003;48:2585–92.PubMedCrossRefGoogle Scholar
  29. 29.
    Allanore Y, Dieude P, Boileau C. Genetic background of systemic sclerosis: autoimmune genes take centre stage. Rheumatology (Oxford). 2010;49:203–10.CrossRefGoogle Scholar
  30. 30.
    Kawaguchi Y, Tochimoto A, Ichikawa N, et al. Association of IL1A gene polymorphisms with susceptibility to and severity of systemic sclerosis in the Japanese population. Arthritis Rheum. 2003;48:186–92.PubMedCrossRefGoogle Scholar
  31. 31.
    Beretta L, Bertolotti F, Cappiello F, et al. Interleukin-1 gene complex polymorphisms in systemic sclerosis patients with severe restrictive lung physiology. Hum Immunol. 2007;68:603–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Sumita Y, Sugiura T, Kawaguchi Y, et al. Genetic polymorphisms in the surfactant proteins in systemic sclerosis in Japanese: T/T genotype at 1580 C/T (Thr131Ile) in the SP-B gene reduces the risk of interstitial lung disease. Rheumatology (Oxford). 2008;47:289–91.CrossRefGoogle Scholar
  33. 33.
    Standardized lung function testing. Official statement of the European Respiratory Society. Eur Respir J Suppl. 1993;16:1–100.Google Scholar
  34. 34.
    Wells AU, King AD, Rubens MB, Cramer D, du Bois RM, Hansell DM. Lone CFA: a functional-morphological correlation based on extent of disease on thin-section computed tomography. Am J Respir Crit Care Med. 1997;155:1367–75.PubMedCrossRefGoogle Scholar
  35. 35.
    Cottin V, Nunes H, Mouthon L, Gamondes D, Lazor R, Hachulla E, et al. Combined pulmonary fibrosis and emphysema syndrome in connective tissue disease. Arthritis Rheum. 2011;63:295–304.PubMedCrossRefGoogle Scholar
  36. 36.
    Nathan SD, Shlobin OA, Ahmad S, Urbanek S, Barnett SD. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest. 2007;131:657–63.PubMedCrossRefGoogle Scholar
  37. 37.
    Steen VD, Graham G, Conte C, Owens G, Medsger Jr TA. Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum. 1992;35:765–70.PubMedCrossRefGoogle Scholar
  38. 38.
    Hughes JMB, Pride NB. Examination of the carbon monoxide diffusing capacity (DLCO) in relation to its KCO and VA components. Am J Respir Crit Care Med. 2012;186:132–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Schurawitzki H, Stiglbauer R, Graninger W, et al. Interstitial lung disease in progressive systemic sclerosis: high resolution CT versus radiography. Radiology. 1990;176:755–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Wells AU, Rubens MB, du Bois RM, Hansell DM. Serial CT in fibrosing alveolitis: prognostic significance of the initial pattern. Am J Roentgenol. 1993;161:1159–65.CrossRefGoogle Scholar
  41. 41.
    Shah RM, Jimenez S, Wechsler R. Significance of ground-glass opacity on HRCT in long-term follow-up of patients with systemic sclerosis. J Thorac Imaging. 2007;22:120–4.PubMedCrossRefGoogle Scholar
  42. 42.
    Wells AU. Forced vital capacity as a primary end-point in idiopathic pulmonary fibrosis treatment trials: making a silk purse from a sow’s ear. Thorax. 2013;68:309–10.PubMedCrossRefGoogle Scholar
  43. 43.
    Goh NS, Desai SR, Anagnostopoulos C, et al. Increased epithelial permeability in pulmonary fibrosis in relation to disease progression. Eur Respir J. 2011;38:184–90.PubMedCrossRefGoogle Scholar
  44. 44.
    Ohnishi H, Yokoyama A, Kondo K, et al. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med. 2002;165:378–81.PubMedCrossRefGoogle Scholar
  45. 45.
    Hasegawa M, Fujimoto M, Hamaguchi Y, et al. Use of serum clara cell 16-kDa (CC16) levels as a potential indicator of active pulmonary fibrosis in systemic sclerosis. J Rheumatol. 2011;38:877–84.PubMedCrossRefGoogle Scholar
  46. 46.
    Bonella F, Volpe A, Caramaschi P, et al. Surfactant protein D and KL-6 serum levels in systemic sclerosis: correlation with lung and systemic involvement. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28:27–33.PubMedGoogle Scholar
  47. 47.
    De Lauretis A, Sestini P, Pantelidis P, et al. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol. 2013;40:435–46.PubMedCrossRefGoogle Scholar
  48. 48.
    Goh NS, Veeraraghavan S, Desai SR, et al. Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. Arthritis Rheum. 2007;56:2005–12.PubMedCrossRefGoogle Scholar
  49. 49.
    Strange C, Bolster MB, Roth MD, Scleroderma Lung Study Research Group, et al. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med. 2008;177:91–8.PubMedCentralPubMedCrossRefGoogle Scholar
  50. 50.
    Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006;54:3962–70.PubMedCrossRefGoogle Scholar
  51. 51.
    Seibold JR, Denton CP, Furst DE, et al. Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum. 2010;62:2101–8.PubMedCrossRefGoogle Scholar
  52. 52.
    Kowal-Bielecka O, Landewe R, Avouac J, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009;68:620–8.PubMedCrossRefGoogle Scholar
  53. 53.
    Tashkin DP, Elashoff R, Clements PJ, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med. 2007;176:1026–34.PubMedCentralPubMedCrossRefGoogle Scholar
  54. 54.
    White B, Moore WC, Wigley FM, Xiao HQ, Wise RA. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med. 2000;132:947–54.PubMedCrossRefGoogle Scholar
  55. 55.
    Nannini C, West CP, Erwin PJ, Matteson EL. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther. 2008;10:R124.PubMedCentralPubMedCrossRefGoogle Scholar
  56. 56.
    Poormoghim H, Moradi Lakeh M, Mohammadipour M, Sodagari F, Toofaninjed N. Cyclophosphamide for scleroderma lung disease: a systemic review and meta-analysis. Rheumatol Int. 2012;32:2431–44. Review.PubMedCrossRefGoogle Scholar
  57. 57.
    Tzouvelekis A, Galanopoulos N, Bouros E, et al. Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysis. Pulm Med. 2012;2012:143637.PubMedCentralPubMedCrossRefGoogle Scholar
  58. 58.
    Fischer A, Brown KK, du Bois RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol. 2013;40:640–6.PubMedCentralPubMedCrossRefGoogle Scholar
  59. 59.
    Steen VD, Medsger Jr TA. Case-control study of corticosteroids and other drugs that could precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum. 1998;41: 1613–9.PubMedCrossRefGoogle Scholar
  60. 60.
    DeMarco PJ, Weisman MH, Seibold JR, et al. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum. 2002;46:2983–9.PubMedCrossRefGoogle Scholar
  61. 61.
    Demedts M, Behr J, Buhl R, et al. High dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005;353:2229–42.PubMedCrossRefGoogle Scholar
  62. 62.
    Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377:1760–9.PubMedCrossRefGoogle Scholar
  63. 63.
    Burt RK, Shah SJ, Dill K, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet. 2011;378:498–506.PubMedCrossRefGoogle Scholar
  64. 64.
    Nash RA, McSweeney PA, Crofford LJ, et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood. 2007;110:1388–96.PubMedCentralPubMedCrossRefGoogle Scholar
  65. 65.
    Daoussis D, Liossis SN, Tsamandas AC, et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology. 2010;49:271–80.PubMedCentralPubMedCrossRefGoogle Scholar
  66. 66.
    Daoussis D, Liossis SN, Tsamandas AC, et al. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol. 2012;30:S17–22.PubMedGoogle Scholar
  67. 67.
    Sem M, Molberg O, Lund MB, Gran JT. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology. 2009;48:968–71.PubMedCrossRefGoogle Scholar
  68. 68.
    Keir GJ, Maher TM, Hansell DM, et al. Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. Eur Respir J. 2012;40:641–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2015

Authors and Affiliations

  • Athol U. Wells
    • 1
  • George A. Margaritopoulos
    • 2
  • Katerina M. Antoniou
    • 3
  • Andrew G. Nicholson
    • 4
  1. 1.Interstitial Lung Disease UnitRoyal Brompton HospitalLondonUK
  2. 2.Department of Thoracic Medicine Medical SchoolUniversity of CreteHeraklionCrete Greece
  3. 3.Head of Molecular and Cellular Pneumonology Laboratory, Department of Thoracic Medicine Medical SchoolUniversity of CreteHeraklionCrete Greece
  4. 4.Department of PathologyRoyal Brompton HospitalLondonUK

Personalised recommendations